Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical development of gefitinib in non-small-cell lung cancer and the Iressa Survival Evaluation in Lung Cancer trial.

Clinical lung cancer - 1 Jan 2005

Price Nancy, Belani Chandra

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to Clinical Trials as Topic
Share to Dose-Response Relationship, Drug
Share to Drug Evaluation, Preclinical

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Gefitinib

Share to Protein-Tyrosine Kinases

Share to Quinazolines

Share to Survival Analysis

Source

Identifiers

PMID: 15694012
DOI: 10.1016/s1525-7304(11)70473-9

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical development of gefitinib in non-small-cell lung cancer and the Iressa Survival Evaluation in Lung Cancer trial.PMID 15694012Read ↗

Gefitinib. Still no convincing results in non-small cell lung cancer.Semantic proximity Read ↗

Gefitinib for non-small-cell lung cancer treatment.Semantic proximity Read ↗

Gefitinib for advanced non-small cell lung cancer.Semantic proximity Read ↗

Long-term safety and survival with gefitinib in select patients with advanced non-small cell lung cancer: Results from the US IRESSA Clinical Access Program (ICAP).Semantic proximity Read ↗

Activity of gefitinib in a non-small-cell lung cancer patient with both activating and resistance EGFR mutations.Semantic proximity Read ↗

Spotlight on gefitinib in non-small-cell lung cancer.Semantic proximity Read ↗

Successful Treatment with Gefitinib in Advanced Non-Small Cell Lung Cancer after Acquired Resistance to Osimertinib.Semantic proximity Read ↗

Management of EGFR Mutation-Positive Non-Small Cell Lung Cancer.Semantic proximity Read ↗

First-line gefitinib therapy for elderly patients with non-small cell lung cancer harboring EGFR mutation: Central Japan Lung Study Group 0901Semantic proximity Read ↗

Combined survival analysis of prospective clinical trials of gefitinib for non-small cell lung cancer with EGFR mutations.Semantic proximity Read ↗

EGFR tyrosine kinase inhibitors in lung cancer: an evolving story.Semantic proximity Read ↗

[China Experts Consensus on Icotinib for Non-small Cell Lung Cancer Treatment (2016 version)].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.